Companies · Other
SCOTTSDALE · Other
Diligence memoA one-page analyst read on Epic Research & Diagnostics, Inc. — recommendation, valuation, rhythm, risks.→Epic Research & Diagnostics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Epic Research & Diagnostics, Inc. is one of 25015 Other companies tracked from SCOTTSDALE. By capital raised it ranks mid-pack (ahead of 61% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Benchmarked against 25015 companies in Other. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 61% of sector peers (real $). Modeled value above 21% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #977 of 1,003.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Zooba Eats, Inc. | Seed | $4.0M | $74.4M | 2.16× |
| EQX Capital, Inc. | Seed | $4.0M | $74.4M | 2.16× |
| Alliance Time Holdings, LLC | Seed | $4.0M | $74.4M | 2.16× |
| Springfield Hockey, LLC | Seed | $4.0M | $74.4M | 2.16× |
| Spring Hill Development Partners, LLC | Seed | $8.0M | $74.4M | 2.16× |
| Ontimeworks, Inc. | Seed | $6.0M | $74.4M | 2.16× |
| OHCP Northeastern Fiber Buyer Holdco, L.P. | Seed | $4.0M | $74.4M | 2.16× |
| American Son Broadway Ltd Liability Co | Seed | $4.0M | $74.4M | 2.16× |
| Capture2, Inc. | Seed | $4.0M | $74.4M | 2.16× |
| Chooze, Corp. | Seed | $4.0M | $74.4M | 2.16× |
| Polybio Capital, L.P. | Seed | $4.0M | $74.4M | 2.16× |
| Equisphere Corp. | Seed | $4.0M | $74.4M | 2.16× |
| Epic Research & Diagnostics, Inc. this company | Seed | $3.8M | $4.0M | 0.12× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $1.4M | 2011-03-18 | $6.9M | $25.7M | 90% |
| Seed | $820K | 2012-11-16 | $4.1M | $15.2M | 90% |
| Seed | $1.4M | 2013-04-29 | $7.0M | $26.1M | 90% |
| Seed | $215K | 2016-07-18 | $1.1M | $4.0M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Robert Hunt | — | 3 other | 2016-07 |
| Thomas P. Smith | — | 3 other | 2013-04 |
| A. Nicholas Rizzo | — | 1 other | 2011-03 |
| Kathleen C. Hanrahan | — | 1 other | 2013-04 |
| Kenneth R. Waters | — | 1 other | 2011-03 |
| Mannie L Jackson | — | 1 other | 2013-04 |
| Michael C. Hammer | — | 1 other | 2011-03 |
| Michael Stowell | — | 1 other | 2011-03 |
| Nancy R. Rizzo | — | 1 other | 2011-03 |
| Roy Carver, Jr. | — | 1 other | 2016-07 |
| Thomas D. Blondi | — | 1 other | 2011-03 |
| Diana Nicholas Hunt | — | — | 2012-11 |
| Diana R. Hunt | — | — | 2011-03 |
| France L Helfer | — | — | 2013-04 |
| Gregg J. Cobb | — | — | 2012-11 |
| Larry J. Ellingson | — | — | 2011-03 |
| Nancy Rizzo | — | — | 2016-07 |
| Nicholas R Rizzo | — | — | 2013-04 |
| Richard Roedel | — | — | 2016-07 |
| Richard Trayler | — | — | 2016-07 |
| Roy J. Carver II | — | — | 2012-11 |
| Roy J. Carver, III | — | — | 2011-03 |
| Roy R Carver III | — | — | 2013-04 |
| Sheryl Von Blucher | — | — | 2016-07 |
Epic Research & Diagnostics, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Epic Research & Diagnostics Inc | Biotechnology | Seed | $3.2M | $85.0M | network4 shared operators · same stage |
| 4Front Ventures Corp. | Other | Seed | $3.6M | $18.0M | network1 shared operator · same sector · same stage |
| Scu L.L.C. | Other | Seed | $5.7M | $5.9M | network1 shared operator · same sector · same stage |
| One King Entertainment, Inc | Other | Seed | $3.8M | $4.0M | same sector · same stage |
| Counsel RB Capital Inc. | Other | Seed | $3.7M | $4.2M | same sector · same stage |
| Centripetal Venture, LLC | Other | Seed | $4.0M | $4.2M | same sector · same stage |
| Nutty Made, Inc. | Other | Seed | $4.0M | $4.2M | same sector · same stage |
| SignaTouch Corp | Other | Seed | $3.5M | $4.0M | same sector · same stage |
See where Epic Research & Diagnostics, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Epic Research & Diagnostics, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.